- Home
- GECC vs QNCX Comparison
GECC vs QNCX Comparison
Compare GECC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- QNCX
- Stock Information
- Founded
- GECC 2016
- QNCX 2012
- Country
- GECC United States
- QNCX United States
- Employees
- GECC N/A
- QNCX N/A
- Industry
- GECC Finance: Consumer Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GECC Finance
- QNCX Health Care
- Exchange
- GECC Nasdaq
- QNCX Nasdaq
- Market Cap
- GECC 127.9M
- QNCX 85.9M
- IPO Year
- GECC N/A
- QNCX 2019
- Fundamental
- Price
- GECC $11.33
- QNCX $1.61
- Analyst Decision
- GECC Strong Buy
- QNCX Strong Buy
- Analyst Count
- GECC 1
- QNCX 6
- Target Price
- GECC $11.50
- QNCX $8.00
- AVG Volume (30 Days)
- GECC 161.3K
- QNCX 143.6K
- Earning Date
- GECC 10-30-2025
- QNCX 11-12-2025
- Dividend Yield
- GECC 13.54%
- QNCX N/A
- EPS Growth
- GECC 29.91
- QNCX N/A
- EPS
- GECC 1.58
- QNCX N/A
- Revenue
- GECC $47,638,000.00
- QNCX N/A
- Revenue This Year
- GECC $28.14
- QNCX N/A
- Revenue Next Year
- GECC N/A
- QNCX N/A
- P/E Ratio
- GECC $7.13
- QNCX N/A
- Revenue Growth
- GECC 29.12
- QNCX N/A
- 52 Week Low
- GECC $8.87
- QNCX $0.69
- 52 Week High
- GECC $11.45
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- GECC 58.13
- QNCX 49.14
- Support Level
- GECC $10.79
- QNCX $1.56
- Resistance Level
- GECC $11.45
- QNCX $1.67
- Average True Range (ATR)
- GECC 0.18
- QNCX 0.07
- MACD
- GECC -0.02
- QNCX 0.00
- Stochastic Oscillator
- GECC 81.95
- QNCX 69.70
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.